Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $889.5 million.

  • Amphastar Pharmaceuticals' Total Liabilities rose 880.44% to $889.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $889.5 million, marking a year-over-year increase of 880.44%. This contributed to the annual value of $845.2 million for FY2024, which is 324.2% down from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Total Liabilities stood at $889.5 million, which was up 880.44% from $857.9 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Total Liabilities high stood at $949.5 million for Q3 2023, and its period low was $194.8 million during Q1 2021.
  • In the last 5 years, Amphastar Pharmaceuticals' Total Liabilities had a median value of $778.2 million in 2024 and averaged $554.7 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 32860.7% in 2023, then crashed by 1390.14% in 2024.
  • Amphastar Pharmaceuticals' Total Liabilities (Quarter) stood at $226.0 million in 2021, then decreased by 5.61% to $213.3 million in 2022, then soared by 309.46% to $873.5 million in 2023, then decreased by 3.24% to $845.2 million in 2024, then rose by 5.24% to $889.5 million in 2025.
  • Its last three reported values are $889.5 million in Q3 2025, $857.9 million for Q2 2025, and $875.0 million during Q1 2025.